- Report
- October 2024
- 192 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
- 143 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- March 2025
- 93 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- September 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- June 2024
- 145 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- October 2024
- 200 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- April 2023
- 115 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- November 2021
- 120 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- July 2024
- 96 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- October 2023
- 146 Pages
Global
From €3353EUR$3,528USD£2,817GBP
€3945EUR$4,150USD£3,314GBP
- Report
- January 2025
- 132 Pages
Global
From €903EUR$950USD£759GBP
- Report
- February 2023
- 248 Pages
Global
From €3394EUR$3,570USD£2,851GBP
The Cardiac Prosthetic Device market is a subset of the Cardiovascular Devices market, which includes a range of products used to diagnose, treat, and manage cardiovascular diseases. Cardiac Prosthetic Devices are used to replace or support the function of a damaged or diseased heart. These devices include artificial heart valves, ventricular assist devices, and total artificial hearts. They are designed to improve the quality of life of patients with heart failure, and to reduce the risk of death from cardiovascular diseases.
Cardiac Prosthetic Devices are typically implanted surgically, and are powered by batteries or other external power sources. They are designed to be durable and reliable, and to provide long-term support for patients with heart failure.
Some of the major companies in the Cardiac Prosthetic Device market include Medtronic, Abbott, Boston Scientific, Edwards Lifesciences, and LivaNova. Show Less Read more
